<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260906070929N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-14</date_registration>
      <primary_sponsor>Shahre-kord University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the Effects of Steroid Injection and TECAR Therapy on Frozen Shoulder</public_title>
      <acronym></acronym>
      <scientific_title>Study and comparison of the course of frozen shoulder after intra-articular steroid injection versus patients treated with TECAR therapy in Shahrekord city : A randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-10-13</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>44</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/93993</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization
Randomization unit: Individual
Measurement tool: Random selection software
Eligible participants who meet the inclusion criteria will be informed about the study, and written informed consent will be obtained before enrollment. Participants will then be randomly assigned to one of two intervention groups: the intra-articular corticosteroid injection group or the TECAR therapy group. Random allocation will be performed using Random Allocation Software.

The study will include 44 participants, with a target of 22 participants in each group. To maintain balanced group sizes throughout recruitment, block randomization may be used to generate the allocation sequence. The allocation sequence will be prepared by an independent individual who is not involved in participant recruitment, treatment administration, or outcome assessment. Allocation concealment will be maintained until each participant has been enrolled and is ready to receive the assigned intervention, using sequentially numbered, opaque, sealed envelopes.

All interventions will be performed by a specialist in Physical Medicine and Rehabilitation. Due to the nature of the interventions, blinding of participants and the treating specialist will not be feasible. However, outcome assessments will be conducted by an orthopedist and a medical student who will remain unaware of the participants’ group assignments. Participants’ demographic and clinical data, treatment allocation, and outcome measurements will be recorded using study identification codes to maintain confidentiality, Blinding description: This study is designed as a single-blind trial. Following the random assignment of patients to two treatment groups, all interventions—including intra-articular steroid injections and TECAR therapy—will be performed by a specialist in physical medicine and rehabilitation. Given the distinct nature of the two treatment modalities, blinding both the patient and the administering physician is not feasible; consequently, both the patients and the treating physician will be aware of the assigned treatment. To minimize assessment bias, the treating physician will assign a specific code to each patient, and patients will be identified solely by these codes. All clinical assessments at the scheduled time points will be conducted by an orthopedist and a student—who will remain unaware of the patients' identities and the specific interventions administered—based exclusively on the patient codes.</study_design>
      <phase>2</phase>
      <hc_freetext>Frozen shoulder.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: They will undergo intraarticular steroid injection. The injection will be performed under ultrasound guidance by a single practitioner (a physical medicine specialist). The medication used will be triamcinolone acetonide (40 mg/mL); a volume of 1 mL will be injected, combined with 2 mL of 1% lidocaine, in a single session. Following the injection, patients will receive instructions regarding relative rest and the performance of gentle pendulum exercises for the shoulder. No other physiotherapy or pharmacological treatment will be prescribed during the follow-up period, so that the isolated effect of the injection can be evaluated. Intervention 2: Intervention group: Patients will undergo Tecar therapy. The treatment will consist of five sessions—each lasting approximately 15 minutes—conducted over a two-week period. The therapy will be administered using a device featuring both capacitive and resistive modes: the capacitive mode will target superficial tissues such as muscles, while the resistive mode will address deeper tissues, including tendons and joint capsules. An experienced physiatrist will perform the treatment, adjusting the current intensity according to the patient's tolerance threshold to ensure a pleasant warming sensation without any burning. Patients will be positioned comfortably and correctly throughout the procedure, and no supplementary medications or injections will be used.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ashkan Salehi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ayatollah Kashani Hospital, Parastar Street, Shahrekord, Chaharmahal and Bakhtiari Province, Iran</address>
        <city>Shahrekord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۸۸۱۶۷۵۸۹۱۵</zip>
        <telephone>+98 38 3226 4839</telephone>
        <email>salehi.ashkan@skums.ac.ir</email>
        <affiliation>Shahre-kord University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ashkan Salehi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ayatollah Kashani Hospital, Parastar Street, Shahrekord, Chaharmahal and Bakhtiari Province, Iran</address>
        <city>Shahrekord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۸۸۱۶۷۵۸۹۱۵</zip>
        <telephone>+98 38 3226 4839</telephone>
        <email>salehi.ashkan@skums.ac.ir</email>
        <affiliation>Shahre-kord University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Developing frozen shoulder
Ages 40 to 60
Willingness and informed consent to participate in the research
Absence of radiculopathy
Absence of osteoarthritis
Absence of severe diabetes
No prior treatment in the shoulder area</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>prior treatment in the shoulder area
Developing severe diabetes
Developing osteoarthritis
Developing radiculopathy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M75.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Adhesive capsulitis of shoulder</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: They will undergo intraarticular steroid injection. The injection will be performed under ultrasound guidance by a single practitioner (a physical medicine specialist). The medication used will be triamcinolone acetonide (40 mg/mL); a volume of 1 mL will be injected, combined with 2 mL of 1% lidocaine, in a single session. Following the injection, patients will receive instructions regarding relative rest and the performance of gentle pendulum exercises for the shoulder. No other physiotherapy or pharmacological treatment will be prescribed during the follow-up period, so that the isolated effect of the injection can be evaluated.</i_keyword>
      <i_keyword>Intervention group: Patients will undergo Tecar therapy. The treatment will consist of five sessions—each lasting approximately 15 minutes—conducted over a two-week period. The therapy will be administered using a device featuring both capacitive and resistive modes: the capacitive mode will target superficial tissues such as muscles, while the resistive mode will address deeper tissues, including tendons and joint capsules. An experienced physiatrist will perform the treatment, adjusting the current intensity according to the patient's tolerance threshold to ensure a pleasant warming sensation without any burning. Patients will be positioned comfortably and correctly throughout the procedure, and no supplementary medications or injections will be used.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Total score of the Shoulder Pain and Disability Index questionnaire. Timepoint: Measurement of the total score on the Shoulder Pain and Disability Index (SPADI) questionnaire at baseline and at 1 and 3 months after the start of treatment. Method of measurement: Pain and Disability Index (SPADI) questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Visual Analogue Scale (VAS) questionnaire score. Timepoint: At baseline, and 1 month and 3 months after the start of treatment. Method of measurement: Visual analogue scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahre-kord University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-09-23</approval_date>
        <contact_name>Research Ethics Committees of School of Medicine - Shahrekord University Of Medical Sciences</contact_name>
        <contact_address>Ayatollah Kashani Hospital, Parastar St., Shahrekord, Chaharmahal and Bakhtiari Province Shahrekord Chahar-Mahal-va-Bakhtiari Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
